IL21

(redirected from Interleukin 21)
Also found in: Wikipedia.

IL21

A gene on chromosome 4q26-q27 that encodes IL-21, a cytokine with immunoregulatory activity that may promote the transition between innate and adaptive immunity. IL21 induces the production of IgG1 and IgG3 in B cells, and may play a role in proliferation and maturation of natural killer cells in synergy with IL15. It is also a less preferred gene symbol for what is now designated as IL17C (see there), as well as IL22 (see there).
References in periodicals archive ?
Project title: Origins of Follicular T cells and Interleukin 21 Signaling in Systemic Lupus Erythematosus
NASDAQ:ZGEN) today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent.
NASDAQ:ZGEN) today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent.
The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
ZymoGenetics' business strategy remains to develop and commercialize recombinant Thrombin while, at the same time, investing in our novel genomics candidates atacicept, Interleukin 21 and PEG-Interferon lambda, as we continue to build the company for the future.
NASDAQ:ZGEN) today announced positive final results from a Phase 2 clinical trial in patients receiving 2nd or 3rd line therapy for advanced renal cell carcinoma with the combination of recombinant Interleukin 21 (IL-21) and Nexavar([R])(sorafenib) tablets.
today announced the upcoming presentation of preliminary results from clinical trials with atacicept in B-cell chronic lymphocytic leukemia and Interleukin 21 (IL-21) in malignant melanoma at the American Society of Clinical Oncology (ASCO) 2007 annual meeting.
The clinical trial evaluated Interleukin 21 (IL-21) in combination with Nexavar([R])(sorafenib) tablets.
Interleukin 21 (IL-21) -- ZymoGenetics is developing IL-21 as a potential treatment for renal cell cancer (RCC), metastatic melanoma and lymphoma in collaboration with Novo Nordisk A/S, which has commercial rights to IL-21 outside North America.
NASDAQ:ZGEN) today announced that Interleukin 21 (IL-21) demonstrated an impressive overall response rate in the treatment of metastatic melanoma.
today announced the start of a Phase 1/2 clinical study of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) in patients with advanced renal cell cancer.
today announced that a Phase 1 clinical trial is underway using Interleukin 21 (IL-21) in combination with the monoclonal antibody Rituxan(R).